GCC Radiopharmaceuticals Market

ID: MRFR/MED/42192-HCR
200 Pages
Rahul Gotadki
Last Updated: April 06, 2026
GCC Radiopharmaceuticals Market Research Report: Size, Share, Trend Analysis By Types (Diagnostic, Therapeutic) and By Applications (Neurology, Cardiology, Oncology, Others) - Growth Outlook & Industry Forecast 2025 To 2035
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

GCC Radiopharmaceuticals Market

Market Size

Forecast Period2025 - 2035
CAGR (2025 - 2035)8.26%
2024 Market Size$ 0.18 Billion
2025 Market Size$ 0.19 Billion
2035 Market Size$ 0.42 Billion

Key Players

Siemens Healthineers
GE Healthcare
Bayer AG
Elekta AB
Bracco Imaging S.p.A.
Lantheus Medical Imaging
Trends
  • Technological Advancements in Imaging
  • Regulatory Support and Investment
  • Focus on Chronic Disease Management
Opportunities
  • Regulatory Framework Enhancements
  • Growing Demand for Diagnostic Imaging
  • Investment in Healthcare Infrastructure
Summary Table of Contents Segmentation Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. 1.1 EXECUTIVE SUMMARY
      1. 1.1.1 Market Overview
      2. 1.1.2 Key Findings
      3. 1.1.3 Market Segmentation
      4. 1.1.4 Competitive Landscape
      5. 1.1.5 Challenges and Opportunities
      6. 1.1.6 Future Outlook
  2. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. 2.1 MARKET INTRODUCTION
      1. 2.1.1 Definition
      2. 2.1.2 Scope of the study
        1. 2.1.2.1 Research Objective
        2. 2.1.2.2 Assumption
        3. 2.1.2.3 Limitations
    2. 2.2 RESEARCH METHODOLOGY
      1. 2.2.1 Overview
      2. 2.2.2 Data Mining
      3. 2.2.3 Secondary Research
      4. 2.2.4 Primary Research
        1. 2.2.4.1 Primary Interviews and Information Gathering Process
        2. 2.2.4.2 Breakdown of Primary Respondents
      5. 2.2.5 Forecasting Model
      6. 2.2.6 Market Size Estimation
        1. 2.2.6.1 Bottom-Up Approach
        2. 2.2.6.2 Top-Down Approach
      7. 2.2.7 Data Triangulation
      8. 2.2.8 Validation
  3. 3 SECTION III: QUALITATIVE ANALYSIS
    1. 3.1 MARKET DYNAMICS
      1. 3.1.1 Overview
      2. 3.1.2 Drivers
      3. 3.1.3 Restraints
      4. 3.1.4 Opportunities
    2. 3.2 MARKET FACTOR ANALYSIS
      1. 3.2.1 Value chain Analysis
      2. 3.2.2 Porter's Five Forces Analysis
        1. 3.2.2.1 Bargaining Power of Suppliers
        2. 3.2.2.2 Bargaining Power of Buyers
        3. 3.2.2.3 Threat of New Entrants
        4. 3.2.2.4 Threat of Substitutes
        5. 3.2.2.5 Intensity of Rivalry
      3. 3.2.3 COVID-19 Impact Analysis
        1. 3.2.3.1 Market Impact Analysis
        2. 3.2.3.2 Regional Impact
        3. 3.2.3.3 Opportunity and Threat Analysis
  4. 4 SECTION IV: QUANTITATIVE ANALYSIS
    1. 4.1 Healthcare, BY Application (USD Billion)
      1. 4.1.1 Oncology
      2. 4.1.2 Cardiology
      3. 4.1.3 Neurology
      4. 4.1.4 Thyroid
      5. 4.1.5 Infectious Diseases
    2. 4.2 Healthcare, BY End Use (USD Billion)
      1. 4.2.1 Hospitals
      2. 4.2.2 Diagnostic Centers
      3. 4.2.3 Research Laboratories
      4. 4.2.4 Pharmaceutical Companies
    3. 4.3 Healthcare, BY Type of Radiopharmaceuticals (USD Billion)
      1. 4.3.1 Diagnostic Radiopharmaceuticals
      2. 4.3.2 Therapeutic Radiopharmaceuticals
      3. 4.3.3 Radioisotopes
      4. 4.3.4 Radiolabeled Compounds
    4. 4.4 Healthcare, BY Distribution Channel (USD Billion)
      1. 4.4.1 Direct Sales
      2. 4.4.2 Distributors
      3. 4.4.3 Online Sales
    5. 4.5 Healthcare, BY Technology (USD Billion)
      1. 4.5.1 Single Photon Emission Computed Tomography
      2. 4.5.2 Positron Emission Tomography
      3. 4.5.3 Radiotherapy
  5. 5 SECTION V: COMPETITIVE ANALYSIS
    1. 5.1 Competitive Landscape
      1. 5.1.1 Overview
      2. 5.1.2 Competitive Analysis
      3. 5.1.3 Market share Analysis
      4. 5.1.4 Major Growth Strategy in the Healthcare
      5. 5.1.5 Competitive Benchmarking
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
      7. 5.1.7 Key developments and growth strategies
        1. 5.1.7.1 New Product Launch/Service Deployment
        2. 5.1.7.2 Merger & Acquisitions
        3. 5.1.7.3 Joint Ventures
      8. 5.1.8 Major Players Financial Matrix
        1. 5.1.8.1 Sales and Operating Income
        2. 5.1.8.2 Major Players R&D Expenditure. 2023
    2. 5.2 Company Profiles
      1. 5.2.1 Siemens Healthineers (DE)
        1. 5.2.1.1 Financial Overview
        2. 5.2.1.2 Products Offered
        3. 5.2.1.3 Key Developments
        4. 5.2.1.4 SWOT Analysis
        5. 5.2.1.5 Key Strategies
      2. 5.2.2 GE Healthcare (US)
        1. 5.2.2.1 Financial Overview
        2. 5.2.2.2 Products Offered
        3. 5.2.2.3 Key Developments
        4. 5.2.2.4 SWOT Analysis
        5. 5.2.2.5 Key Strategies
      3. 5.2.3 Bayer AG (DE)
        1. 5.2.3.1 Financial Overview
        2. 5.2.3.2 Products Offered
        3. 5.2.3.3 Key Developments
        4. 5.2.3.4 SWOT Analysis
        5. 5.2.3.5 Key Strategies
      4. 5.2.4 Elekta AB (SE)
        1. 5.2.4.1 Financial Overview
        2. 5.2.4.2 Products Offered
        3. 5.2.4.3 Key Developments
        4. 5.2.4.4 SWOT Analysis
        5. 5.2.4.5 Key Strategies
      5. 5.2.5 Bracco Imaging S.p.A. (IT)
        1. 5.2.5.1 Financial Overview
        2. 5.2.5.2 Products Offered
        3. 5.2.5.3 Key Developments
        4. 5.2.5.4 SWOT Analysis
        5. 5.2.5.5 Key Strategies
      6. 5.2.6 Lantheus Medical Imaging, Inc. (US)
        1. 5.2.6.1 Financial Overview
        2. 5.2.6.2 Products Offered
        3. 5.2.6.3 Key Developments
        4. 5.2.6.4 SWOT Analysis
        5. 5.2.6.5 Key Strategies
      7. 5.2.7 Cardinal Health, Inc. (US)
        1. 5.2.7.1 Financial Overview
        2. 5.2.7.2 Products Offered
        3. 5.2.7.3 Key Developments
        4. 5.2.7.4 SWOT Analysis
        5. 5.2.7.5 Key Strategies
      8. 5.2.8 NorthStar Medical Radioisotopes, LLC (US)
        1. 5.2.8.1 Financial Overview
        2. 5.2.8.2 Products Offered
        3. 5.2.8.3 Key Developments
        4. 5.2.8.4 SWOT Analysis
        5. 5.2.8.5 Key Strategies
    3. 5.3 Appendix
      1. 5.3.1 References
      2. 5.3.2 Related Reports
  6. 6 LIST OF FIGURES
    1. 6.1 MARKET SYNOPSIS
    2. 6.2 GCC MARKET ANALYSIS BY APPLICATION
    3. 6.3 GCC MARKET ANALYSIS BY END USE
    4. 6.4 GCC MARKET ANALYSIS BY TYPE OF RADIOPHARMACEUTICALS
    5. 6.5 GCC MARKET ANALYSIS BY DISTRIBUTION CHANNEL
    6. 6.6 GCC MARKET ANALYSIS BY TECHNOLOGY
    7. 6.7 KEY BUYING CRITERIA OF HEALTHCARE
    8. 6.8 RESEARCH PROCESS OF MRFR
    9. 6.9 DRO ANALYSIS OF HEALTHCARE
    10. 6.10 DRIVERS IMPACT ANALYSIS: HEALTHCARE
    11. 6.11 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
    12. 6.12 SUPPLY / VALUE CHAIN: HEALTHCARE
    13. 6.13 HEALTHCARE, BY APPLICATION, 2024 (% SHARE)
    14. 6.14 HEALTHCARE, BY APPLICATION, 2024 TO 2035 (USD Billion)
    15. 6.15 HEALTHCARE, BY END USE, 2024 (% SHARE)
    16. 6.16 HEALTHCARE, BY END USE, 2024 TO 2035 (USD Billion)
    17. 6.17 HEALTHCARE, BY TYPE OF RADIOPHARMACEUTICALS, 2024 (% SHARE)
    18. 6.18 HEALTHCARE, BY TYPE OF RADIOPHARMACEUTICALS, 2024 TO 2035 (USD Billion)
    19. 6.19 HEALTHCARE, BY DISTRIBUTION CHANNEL, 2024 (% SHARE)
    20. 6.20 HEALTHCARE, BY DISTRIBUTION CHANNEL, 2024 TO 2035 (USD Billion)
    21. 6.21 HEALTHCARE, BY TECHNOLOGY, 2024 (% SHARE)
    22. 6.22 HEALTHCARE, BY TECHNOLOGY, 2024 TO 2035 (USD Billion)
    23. 6.23 BENCHMARKING OF MAJOR COMPETITORS
  7. 7 LIST OF TABLES
    1. 7.1 LIST OF ASSUMPTIONS
  8. 7.1.1
    1. 7.2 GCC MARKET SIZE ESTIMATES; FORECAST
      1. 7.2.1 BY APPLICATION, 2026-2035 (USD Billion)
      2. 7.2.2 BY END USE, 2026-2035 (USD Billion)
      3. 7.2.3 BY TYPE OF RADIOPHARMACEUTICALS, 2026-2035 (USD Billion)
      4. 7.2.4 BY DISTRIBUTION CHANNEL, 2026-2035 (USD Billion)
      5. 7.2.5 BY TECHNOLOGY, 2026-2035 (USD Billion)
    2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  9. 7.3.1
    1. 7.4 ACQUISITION/PARTNERSHIP
  10. 7.4.1

GCC Radiopharmaceuticals Market Segmentation

GCC Radiopharmaceuticals Market By Application (USD Billion, 2026-2035)

  • Oncology
  • Cardiology
  • Neurology
  • Thyroid
  • Infectious Diseases

GCC Radiopharmaceuticals Market By End Use (USD Billion, 2026-2035)

  • Hospitals
  • Diagnostic Centers
  • Research Laboratories
  • Pharmaceutical Companies

GCC Radiopharmaceuticals Market By Type of Radiopharmaceuticals (USD Billion, 2026-2035)

  • Diagnostic Radiopharmaceuticals
  • Therapeutic Radiopharmaceuticals
  • Radioisotopes
  • Radiolabeled Compounds

GCC Radiopharmaceuticals Market By Distribution Channel (USD Billion, 2026-2035)

  • Direct Sales
  • Distributors
  • Online Sales

GCC Radiopharmaceuticals Market By Technology (USD Billion, 2026-2035)

  • Single Photon Emission Computed Tomography
  • Positron Emission Tomography
  • Radiotherapy

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories

Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035